Targeting the Tiam1-Rac pathway therapeutically remains a subject of ongoing investigation, due to the dramatic reduction in tumour formation following loss of Tiam1 in animal models (Malliri et al., 2006, 2002). This evidence concerns the gene AKT1 and neoplasm.